Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.41 |
| ▸ | CTSS | P25774 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31226519 | 1.00 | CTSK (0.41) | CTSKCTSSTSHRALDH1A1HSD17B10 | |
| SCHEMBL31226504 | 0.90 | ALDH1A1 (0.38) | CTSKCTSSTSHRALDH1A1HSD17B10 | |
| SCHEMBL31226508 | 0.90 | ALDH1A1 (0.38) | CTSKCTSSTSHRALDH1A1HSD17B10 | |
| SCHEMBL31226215 | 0.90 | ALDH1A1 (0.38) | CTSKCTSSTSHRALDH1A1HSD17B10 | |
| SCHEMBL31226370 | 0.88 | HSD17B10 (0.36) | CTSKTSHRALDH1A1HSD17B10CYP2D6 | |
| SCHEMBL31226231 | 0.86 | ALDH1A1 (0.36) | TSHRALDH1A1HSD17B10CYP2D6 | |
| SCHEMBL31226394 | 0.86 | ALDH1A1 (0.36) | TSHRALDH1A1HSD17B10CYP2D6 | |
| SCHEMBL31226705 | 0.86 | ALDH1A1 (0.36) | TSHRALDH1A1HSD17B10CYP2D6 | |
| SCHEMBL1419503 | 0.85 | CTSK (0.41) | CTSKCTSSTSHRALDH1A1MAPT | |
| SCHEMBL31226324 | 0.85 | SYK (0.37) | CTSKCTSSTSHRALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709712-A1 | GSK3A INHIBITORS AND METHODS OF USE THEREOF | Blueprint Medicines Corporation (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024233900-A1 | GSK3A INHIBITORS AND METHODS OF USE THEREOF | BLUEPRINT MEDICINES CORPORATION (US) | 2024-11-14 | — | — | WO | disclosed |